NASDAQ:CKPT

Checkpoint Therapeutics Competitors

$2.68
-0.12 (-4.29 %)
(As of 04/20/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.63
Now: $2.68
$2.80
50-Day Range
$2.80
MA: $3.18
$3.58
52-Week Range
$1.44
Now: $2.68
$5.38
Volume1.43 million shs
Average Volume1.35 million shs
Market Capitalization$201.57 million
P/E RatioN/A
Dividend YieldN/A
Beta1.66

Competitors

Checkpoint Therapeutics (NASDAQ:CKPT) Vs. COLL, ARDX, EPZM, ESPR, ORIC, and HGEN

Should you be buying CKPT stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Checkpoint Therapeutics, including Collegium Pharmaceutical (COLL), Ardelyx (ARDX), Epizyme (EPZM), Esperion Therapeutics (ESPR), ORIC Pharmaceuticals (ORIC), and Humanigen (HGEN).

Collegium Pharmaceutical (NASDAQ:COLL) and Checkpoint Therapeutics (NASDAQ:CKPT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, valuation, earnings and risk.

Risk and Volatility

Collegium Pharmaceutical has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500. Comparatively, Checkpoint Therapeutics has a beta of 1.66, meaning that its stock price is 66% more volatile than the S&P 500.

Valuation and Earnings

This table compares Collegium Pharmaceutical and Checkpoint Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Collegium Pharmaceutical$296.70 million2.71$-22,720,000.00($0.68)-33.54
Checkpoint Therapeutics$1.71 million117.88$-24,710,000.00($0.70)-3.83

Collegium Pharmaceutical has higher revenue and earnings than Checkpoint Therapeutics. Collegium Pharmaceutical is trading at a lower price-to-earnings ratio than Checkpoint Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

18.8% of Checkpoint Therapeutics shares are owned by institutional investors. 8.1% of Collegium Pharmaceutical shares are owned by company insiders. Comparatively, 7.8% of Checkpoint Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations for Collegium Pharmaceutical and Checkpoint Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Collegium Pharmaceutical11202.25
Checkpoint Therapeutics00303.00

Collegium Pharmaceutical presently has a consensus target price of $25.00, indicating a potential upside of 9.60%. Checkpoint Therapeutics has a consensus target price of $17.6667, indicating a potential upside of 559.20%. Given Checkpoint Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Checkpoint Therapeutics is more favorable than Collegium Pharmaceutical.

Profitability

This table compares Collegium Pharmaceutical and Checkpoint Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Collegium Pharmaceutical5.71%12.64%3.15%
Checkpoint Therapeutics-2,032.05%-100.54%-75.09%

Summary

Collegium Pharmaceutical beats Checkpoint Therapeutics on 8 of the 14 factors compared between the two stocks.

Ardelyx (NASDAQ:ARDX) and Checkpoint Therapeutics (NASDAQ:CKPT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, valuation, earnings and risk.

Risk and Volatility

Ardelyx has a beta of 2.02, meaning that its stock price is 102% more volatile than the S&P 500. Comparatively, Checkpoint Therapeutics has a beta of 1.66, meaning that its stock price is 66% more volatile than the S&P 500.

Valuation and Earnings

This table compares Ardelyx and Checkpoint Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ardelyx$5.28 million150.82$-94,940,000.00($1.47)-5.49
Checkpoint Therapeutics$1.71 million117.88$-24,710,000.00($0.70)-3.83

Checkpoint Therapeutics has lower revenue, but higher earnings than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Checkpoint Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

85.9% of Ardelyx shares are owned by institutional investors. Comparatively, 18.8% of Checkpoint Therapeutics shares are owned by institutional investors. 4.0% of Ardelyx shares are owned by company insiders. Comparatively, 7.8% of Checkpoint Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations for Ardelyx and Checkpoint Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ardelyx00403.00
Checkpoint Therapeutics00303.00

Ardelyx presently has a consensus target price of $14.00, indicating a potential upside of 73.48%. Checkpoint Therapeutics has a consensus target price of $17.6667, indicating a potential upside of 559.20%. Given Checkpoint Therapeutics' higher probable upside, analysts plainly believe Checkpoint Therapeutics is more favorable than Ardelyx.

Profitability

This table compares Ardelyx and Checkpoint Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ardelyx-1,063.74%-53.93%-37.42%
Checkpoint Therapeutics-2,032.05%-100.54%-75.09%

Summary

Ardelyx beats Checkpoint Therapeutics on 8 of the 13 factors compared between the two stocks.

Epizyme (NASDAQ:EPZM) and Checkpoint Therapeutics (NASDAQ:CKPT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, valuation, earnings and risk.

Insider and Institutional Ownership

89.8% of Epizyme shares are owned by institutional investors. Comparatively, 18.8% of Checkpoint Therapeutics shares are owned by institutional investors. 16.3% of Epizyme shares are owned by company insiders. Comparatively, 7.8% of Checkpoint Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations for Epizyme and Checkpoint Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Epizyme04302.43
Checkpoint Therapeutics00303.00

Epizyme presently has a consensus target price of $16.5714, indicating a potential upside of 114.10%. Checkpoint Therapeutics has a consensus target price of $17.6667, indicating a potential upside of 559.20%. Given Checkpoint Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Checkpoint Therapeutics is more favorable than Epizyme.

Profitability

This table compares Epizyme and Checkpoint Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Epizyme-1,899.35%-83.45%-52.66%
Checkpoint Therapeutics-2,032.05%-100.54%-75.09%

Risk and Volatility

Epizyme has a beta of 1.76, meaning that its stock price is 76% more volatile than the S&P 500. Comparatively, Checkpoint Therapeutics has a beta of 1.66, meaning that its stock price is 66% more volatile than the S&P 500.

Valuation and Earnings

This table compares Epizyme and Checkpoint Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Epizyme$23.80 million33.10$-170,290,000.00($1.93)-4.01
Checkpoint Therapeutics$1.71 million117.88$-24,710,000.00($0.70)-3.83

Checkpoint Therapeutics has lower revenue, but higher earnings than Epizyme. Epizyme is trading at a lower price-to-earnings ratio than Checkpoint Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Epizyme beats Checkpoint Therapeutics on 8 of the 13 factors compared between the two stocks.

Checkpoint Therapeutics (NASDAQ:CKPT) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

Insider & Institutional Ownership

18.8% of Checkpoint Therapeutics shares are owned by institutional investors. 7.8% of Checkpoint Therapeutics shares are owned by insiders. Comparatively, 7.7% of Esperion Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings for Checkpoint Therapeutics and Esperion Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Checkpoint Therapeutics00303.00
Esperion Therapeutics24312.30

Checkpoint Therapeutics presently has a consensus price target of $17.6667, indicating a potential upside of 559.20%. Esperion Therapeutics has a consensus price target of $50.60, indicating a potential upside of 83.73%. Given Checkpoint Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Checkpoint Therapeutics is more favorable than Esperion Therapeutics.

Profitability

This table compares Checkpoint Therapeutics and Esperion Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Checkpoint Therapeutics-2,032.05%-100.54%-75.09%
Esperion Therapeutics-46.15%-629.88%-41.43%

Risk and Volatility

Checkpoint Therapeutics has a beta of 1.66, suggesting that its share price is 66% more volatile than the S&P 500. Comparatively, Esperion Therapeutics has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500.

Valuation & Earnings

This table compares Checkpoint Therapeutics and Esperion Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Checkpoint Therapeutics$1.71 million117.88$-24,710,000.00($0.70)-3.83
Esperion Therapeutics$148.36 million5.23$-97,170,000.00($3.59)-7.67

Checkpoint Therapeutics has higher earnings, but lower revenue than Esperion Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Checkpoint Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Checkpoint Therapeutics beats Esperion Therapeutics on 10 of the 14 factors compared between the two stocks.

Checkpoint Therapeutics (NASDAQ:CKPT) and ORIC Pharmaceuticals (NASDAQ:ORIC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

Insider & Institutional Ownership

18.8% of Checkpoint Therapeutics shares are owned by institutional investors. Comparatively, 73.4% of ORIC Pharmaceuticals shares are owned by institutional investors. 7.8% of Checkpoint Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings for Checkpoint Therapeutics and ORIC Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Checkpoint Therapeutics00303.00
ORIC Pharmaceuticals01602.86

Checkpoint Therapeutics presently has a consensus price target of $17.6667, indicating a potential upside of 559.20%. ORIC Pharmaceuticals has a consensus price target of $43.7143, indicating a potential upside of 107.97%. Given Checkpoint Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Checkpoint Therapeutics is more favorable than ORIC Pharmaceuticals.

Profitability

This table compares Checkpoint Therapeutics and ORIC Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Checkpoint Therapeutics-2,032.05%-100.54%-75.09%
ORIC PharmaceuticalsN/AN/AN/A

Valuation & Earnings

This table compares Checkpoint Therapeutics and ORIC Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Checkpoint Therapeutics$1.71 million117.88$-24,710,000.00($0.70)-3.83
ORIC PharmaceuticalsN/AN/AN/AN/AN/A

ORIC Pharmaceuticals has lower revenue, but higher earnings than Checkpoint Therapeutics.

Summary

ORIC Pharmaceuticals beats Checkpoint Therapeutics on 5 of the 9 factors compared between the two stocks.

Checkpoint Therapeutics (NASDAQ:CKPT) and Humanigen (NASDAQ:HGEN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

Risk and Volatility

Checkpoint Therapeutics has a beta of 1.66, suggesting that its share price is 66% more volatile than the S&P 500. Comparatively, Humanigen has a beta of -0.79, suggesting that its share price is 179% less volatile than the S&P 500.

Profitability

This table compares Checkpoint Therapeutics and Humanigen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Checkpoint Therapeutics-2,032.05%-100.54%-75.09%
HumanigenN/A-302.90%-174.74%

Analyst Ratings

This is a breakdown of current ratings for Checkpoint Therapeutics and Humanigen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Checkpoint Therapeutics00303.00
Humanigen01502.83

Checkpoint Therapeutics presently has a consensus price target of $17.6667, indicating a potential upside of 559.20%. Humanigen has a consensus price target of $29.8333, indicating a potential upside of 120.33%. Given Checkpoint Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Checkpoint Therapeutics is more favorable than Humanigen.

Insider & Institutional Ownership

18.8% of Checkpoint Therapeutics shares are owned by institutional investors. Comparatively, 30.2% of Humanigen shares are owned by institutional investors. 7.8% of Checkpoint Therapeutics shares are owned by insiders. Comparatively, 37.5% of Humanigen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Checkpoint Therapeutics and Humanigen's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Checkpoint Therapeutics$1.71 million117.88$-24,710,000.00($0.70)-3.83
HumanigenN/AN/A$-10,290,000.00N/AN/A

Humanigen has lower revenue, but higher earnings than Checkpoint Therapeutics.

Summary

Checkpoint Therapeutics beats Humanigen on 6 of the 11 factors compared between the two stocks.

Ad PulseStocks
Lithium Technology Stock
EV stock's market-disrupting technology improves cost, durability of lithium cathodes

Checkpoint Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Collegium Pharmaceutical logo
COLL
Collegium Pharmaceutical
1.4$22.81-2.0%$803.00 million$296.70 million46.55Analyst Revision
Ardelyx logo
ARDX
Ardelyx
1.6$8.07-9.0%$796.35 million$5.28 million-7.99Increase in Short Interest
Epizyme logo
EPZM
Epizyme
1.8$7.74-0.1%$787.82 million$23.80 million-3.47Analyst Report
News Coverage
Esperion Therapeutics logo
ESPR
Esperion Therapeutics
1.2$27.54-2.4%$775.42 million$148.36 million-7.15
ORIC Pharmaceuticals logo
ORIC
ORIC Pharmaceuticals
1.7$21.02-0.1%$771.33 millionN/A0.00Increase in Short Interest
Humanigen logo
HGEN
Humanigen
1.7$13.54-2.6%$724.15 millionN/A0.00Analyst Report
News Coverage
Karyopharm Therapeutics logo
KPTI
Karyopharm Therapeutics
1.7$9.44-2.2%$708.58 million$40.89 million-3.26News Coverage
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$4.88-0.8%$704.45 million$322.07 million-4.65Upcoming Earnings
Decrease in Short Interest
News Coverage
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$20.80-2.9%$689.77 million$252 million-2.13
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.17-0.9%$682.20 million$150,000.00-4.53News Coverage
Chimerix logo
CMRX
Chimerix
1.3$7.91-1.8%$677.72 million$12.52 million-13.88
Bicycle Therapeutics logo
BCYC
Bicycle Therapeutics
1.3$29.32-4.2%$677.00 million$13.80 million-14.16Analyst Report
News Coverage
Xenon Pharmaceuticals logo
XENE
Xenon Pharmaceuticals
1.6$18.55-6.8%$664.26 million$6.83 million-19.12
VBI Vaccines logo
VBIV
VBI Vaccines
1.5$2.61-1.1%$662.95 million$2.22 million-15.35News Coverage
Gap Down
Kadmon logo
KDMN
Kadmon
1.8$3.83-3.1%$658.06 million$5.09 million-6.38
Calliditas Therapeutics AB (publ) logo
CALT
Calliditas Therapeutics AB (publ)
1.4$26.02-3.4%$649.75 million$19.56 million-18.72
Syndax Pharmaceuticals logo
SNDX
Syndax Pharmaceuticals
1.6$13.42-44.4%$647.33 million$1.52 million-7.14High Trading Volume
Increase in Short Interest
News Coverage
Gap Up
Veru logo
VERU
Veru
1.4$8.88-2.4%$638.58 million$42.59 million-31.71Analyst Report
Chinook Therapeutics logo
KDNY
Chinook Therapeutics
1.4$14.67-4.6%$621.67 million$17.26 million-4.08
Gossamer Bio logo
GOSS
Gossamer Bio
1.7$8.20-2.1%$619.33 millionN/A-2.30Increase in Short Interest
News Coverage
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.55-2.0%$603.93 million$59.29 million-23.67Increase in Short Interest
News Coverage
Albireo Pharma logo
ALBO
Albireo Pharma
1.5$31.51-4.4%$602.28 million$9.64 million-5.13
AnaptysBio logo
ANAB
AnaptysBio
1.5$21.91-0.7%$599.59 million$8 million-8.08
IDEAYA Biosciences logo
IDYA
IDEAYA Biosciences
1.5$18.56-1.0%$598.75 millionN/A-9.87Analyst Report
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$5.67-1.9%$592.69 million$143.01 million-1.08
SIGA Technologies logo
SIGA
SIGA Technologies
0.3$7.58-5.3%$581.37 million$26.74 million18.94News Coverage
Relmada Therapeutics logo
RLMD
Relmada Therapeutics
1.1$34.67-0.5%$580.62 millionN/A-16.05
Evelo Biosciences logo
EVLO
Evelo Biosciences
1.9$10.84-6.5%$578.15 millionN/A-4.35Analyst Upgrade
News Coverage
KalVista Pharmaceuticals logo
KALV
KalVista Pharmaceuticals
1.8$23.61-2.1%$573.91 million$12.69 million-11.35Increase in Short Interest
News Coverage
Gap Up
Eagle Pharmaceuticals logo
EGRX
Eagle Pharmaceuticals
1.2$42.87-0.6%$566.61 million$195.89 million122.49
Crinetics Pharmaceuticals logo
CRNX
Crinetics Pharmaceuticals
1.8$16.55-2.3%$546.63 million$1.19 million-6.90
Mirum Pharmaceuticals logo
MIRM
Mirum Pharmaceuticals
1.8$17.86-0.6%$543.69 millionN/A-5.19
OrganiGram logo
OGI
OrganiGram
1.6$2.34-11.1%$543.51 million$64.61 million-3.44Analyst Downgrade
Decrease in Short Interest
Gap Down
Urovant Sciences logo
UROV
Urovant Sciences
0.7$16.24-0.0%$531.75 millionN/A-3.15
IVERIC bio logo
ISEE
IVERIC bio
1.5$5.84-1.0%$526.59 millionN/A-4.63News Coverage
Aldeyra Therapeutics logo
ALDX
Aldeyra Therapeutics
1.4$11.02-1.1%$523.94 millionN/A-8.54
89bio logo
ETNB
89bio
1.6$25.81-1.9%$517.10 millionN/A-5.11Insider Selling
CytomX Therapeutics logo
CTMX
CytomX Therapeutics
1.6$7.96-4.5%$515.68 million$57.49 million-6.69News Coverage
Magenta Therapeutics logo
MGTA
Magenta Therapeutics
1.3$10.61-1.0%$515.18 millionN/A-5.44
RAPT Therapeutics logo
RAPT
RAPT Therapeutics
1.6$20.64-3.0%$513.23 millionN/A-8.13
Inventiva logo
IVA
Inventiva
0.0$13.27-0.9%$512.62 millionN/A0.00
Neoleukin Therapeutics logo
NLTX
Neoleukin Therapeutics
1.4$12.04-0.2%$509.61 million$25 million-18.52
Marinus Pharmaceuticals logo
MRNS
Marinus Pharmaceuticals
1.7$13.85-1.2%$507.37 millionN/A-3.99
Akouos logo
AKUS
Akouos
1.6$14.60-2.4%$502.27 millionN/A0.00
Provention Bio logo
PRVB
Provention Bio
1.6$7.81-3.1%$494.96 millionN/A-5.24Analyst Report
Increase in Short Interest
XBiotech logo
XBIT
XBiotech
1.0$16.48-1.7%$485.48 millionN/A1.14News Coverage
Amryt Pharma logo
AMYT
Amryt Pharma
1.4$13.50-1.9%$484.34 million$58.12 million-15.70Gap Up
Avadel Pharmaceuticals logo
AVDL
Avadel Pharmaceuticals
1.5$8.18-3.5%$478.24 million$59.22 million40.90
AC Immune logo
ACIU
AC Immune
1.3$6.51-0.0%$468.31 million$111.75 million-7.23Analyst Upgrade
Analyst Revision
Verastem logo
VSTM
Verastem
1.3$2.71-0.4%$465.22 million$17.46 million-1.92
This page was last updated on 4/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.